Cytoreductive Surgery and Hyperthermic İntraperitoneal Chemoterapy for Advance Gastric Cancer Associated Peritoneal Carcinomatosis Single Centre Unit for 10 Consecutive Patients

• Published in: Haseki tıp bülteni Vol. 57; no. 3; p. 267
• Main Authors: Düzgün, Özgül, Yüksekdağ, Sema, Kalın, Murat, Çomoğlu, Şenol, Yanık, Semra, Özkan, Ömer Faruk, Köksal, Neşet
• Format: Journal Article
• Language: Turkish
• Published: Istanbul Galenos Publishing House 01-09-2019
• Subjects: Biopsy; Chemotherapy; Fever; Gastric cancer; Hyperthermia; Surgery; Systematic review; United States > US
• ISSN: 1302-0072; 2147-2688
• DOI: 10.4274/haseki.galenos.2019.4997

Aim: Hyperthermic intraperitoneal chemotherapy with cytoreductive surgery has a positive effect on survival in advanced abdominal cancers. We aimed to present our experience with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer patients with peritoneal carcinomatosis and a review of the literature. Methods: Ten patients (seven male, three female) who were diagnosed with gastric cancer between June 2017 and November 2018 were included in the study. Data on demographic characteristics, short-term follow-up results, surgical findings, peritoneal carcinomatosis index score, completeness of cytoreduction score, and morbidity and mortality rates were retrospectively analyzed. Results: The mean age of the patients was 60.3 years. The mean follow-up period was six months (1-15 months). One patient developed an anastomotic leak. In the other nine cases, there was no morbidity leading to mortality. Conclusion: While gastric cancer with peritoneal carcinomatos has a poor survival, less than six months with non-operative approach, treatment with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy offers better outcomes and overall survival. Our first results in our study with a limited number of patients are satisfactory and multicentric randomized studies are needed on this subject.